Recombinant human erythropoietin attenuates renal tubulointerstitial injury in murine adriamycin-induced nephropathy

Journal of Nephrology

Volumn 26, Issue 3, 2013, Pages 527-533

  Nakazawa, Yuka ^a   Nishino, Tomoya ^a   Obata, Yoko ^a,b   Nakazawa, Masayuki ^a   Furusu, Akira ^a   Abe, Katsushige ^c   Miyazaki, Masanobu ^d   Koji, Takehiko ^e   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^c Jinikai Hospital   (Japan)

^d Miyazaki Clinic   (Japan)

^e NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Adriamycin; Apoptosis; Erythropoietin; Ischemia; Tubulointerstitial injury

Indexed keywords

CASPASE 3; CD34 ANTIGEN; DOXORUBICIN; ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; PROTEIN KINASE B; RECOMBINANT ERYTHROPOIETIN;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL HYPOXIA; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; GLOMERULUS; HEMATOCRIT; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASE; KIDNEY INJURY; KIDNEY TUBULE EPITHELIUM; MALE; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RENAL PROTECTION; RENAL TUBULOINTERSTITIAL INJURY;

ANIMALS; DOXORUBICIN; ERYTHROPOIETIN; KIDNEY DISEASES; KIDNEY TUBULES; MALE; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS;

EID: 84877960065     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000178     Document Type: Article

References (22)

1. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 1998;339(20):1448-1456.
2. Mezzano SA, Barría M, Droguett MA, et al. Tubular NF-kappaB and AP-1 activation in human proteinuric renal disease. Kidney Int. 2001;60(4):1366-1377.
3. Kang D-H, Kanellis J, Hugo C, et al. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol. 2002;13(3):806-816.
4. Youssoufian H, Longmore G, Neumann D, Yoshimura A, Lodish HF. Structure, function, and activation of the erythropoietin receptor. Blood. 1993;81(9):2223-2236.
5. Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy MO. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J. 2004;18(9):1031-1033.
6. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int. 1999;55(3):808-820.
7. Junk AK, Mammis A, Savitz SI, et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci USA. 2002;99(16):10659-10664.
8. Abdelrahman M, Sharples EJ, McDonald MC, et al. Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock. 2004;22(1):63-69.
9. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA. 2000;97(19):10526-10531.
10. Celik M, Gökmen N, Erbayraktar S, et al. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci USA. 2002;99(4):2258-2263.
11. Heeschen C, Aicher A, Lehmann R, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood. 2003;102(4):1340-1346.
12. Buemi M, Galeano M, Sturiale A, et al. Recombinant human erythropoietin stimulates angiogenesis and healing of ischemic skin wounds. Shock. 2004;22(2):169-173.
13. Yang CW, Li C, Jung JY, et al. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J. 2003;17(12):1754-1755.
14. Lee SH, Li C, Lim SW, et al. Attenuation of interstitial inflammation and fibrosis by recombinant human erythropoietin in chronic cyclosporine nephropathy. Am J Nephrol. 2005;25(1):64-76.
15. Bagnis C, Beaufils H, Jacquiaud C, et al. Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant. 2001;16(5):932-938.
16. Bahlmann FH, Song R, Boehm SM, et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation. 2004;110(8):1006-1012.
17. Noiri E, Nagano N, Negishi K, et al. Efficacy of darbepoetin in doxorubicin-induced cardiorenal injury in rats. Nephron Exp Nephrol. 2006;104(1):e6-e14.
18. Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ. Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol. 2001;12(7):1448-1457.
19. Lacombe C, Mayeux P. The molecular biology of erythropoietin. Nephrol Dial Transplant. 1999;14(90002)(Suppl 2):22-28.
20. Kashii Y, Uchida M, Kirito K, et al. A member of Forkhead family transcription factor, FKHRL1, is one of the downstream molecules of phosphatidylinositol 3-kinase-Akt activation pathway in erythropoietin signal transduction. Blood. 2000; 96(3):941-949.
21. Chong ZZ, Lin SH, Kang JQ, Maiese K. Erythropoietin prevents early and late neuronal demise through modulation of Akt1 and induction of caspase 1, 3, and 8. J Neurosci Res. 2003;71(5):659-669.
22. Wang Y, Wang YP, Tay YC, Harris DC. Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. Kidney Int. 2000;58(4):1797-1804.